Integration of Nanoparticle Technology in Osteosarcoma Treatment: From Bench to Bedside
Location
Suwanee, GA
Start Date
17-4-2026 12:00 PM
End Date
17-4-2026 1:00 PM
Description
INTRODUCTION: Osteosarcoma is a malignant tumor, arising from mesenchymal stem cells located in the metaphyseal region of the long bones. These tumors commonly manifest in a bimodal distribution of children, adolescents, and young adults, with a secondary incidence in the elderly. Osteosarcoma is characterized by complex genomic instability rather than a single driver mutation, with commonly altered genes including TP53, RB1, ATRX, and MDM2. The tumors prefer to be in an acidic, low-oxygen environment that promotes matrix metalloproteinase (MMP) secretion, leading to bone destruction through RANKL pathway activation, pathological angiogenesis, and pulmonary metastasis. Despite the establishment of first-line chemotherapeutic treatment regimens (MAP protocol: cisplatin, doxorubicin, and high-dose methotrexate), traditional treatments expose patients to significant systemic toxicities and chemotherapeutic resistance. Nanoparticle technology offers a highly adaptable platform for targeted drug delivery that addresses these limitations. Structurally, nanoparticles are composed of a core that encapsulates or binds a therapeutic payload and a surface layer that can be chemically engineered to regulate pharmacokinetics, immune recognition, and tissue-specific targeting. Overall, the integration of nanoparticle carriers into osteosarcoma therapy represents an advancement in overcoming therapeutic resistance, minimizing systemic toxicity, and improving patient quality of life.
METHODS: This literature review of nanoparticle technology was conducted utilizing PubMed, NIH, and EBSCO databases, with first-line treatment approaches guided by the National Comprehensive Cancer Network (NCCN). Selected studies incorporated nanoparticle formulations combined with first-line agents. Discussion is organized by preclinical (in vitro and in vivo) and clinical trial evidence.
RESULTS: Among the various nanoparticle modalities, nanostructured lipid carriers (NLCs) represent a particularly promising approach due to biocompatibility, high drug-loading capacity, and sustained-release properties. Hao Li et al. (2025) conducted in vitro and in vivo studies to determine whether combining methotrexate and cucurbitacin with a nanoparticle lipid (MTX-CuB-NLC) carrier can prevent drug resistance, a major barrier to treatment initiation. In the vitro study, they used both solid and liquid lipids to formulate the delivery system, thereby improving drug delivery. They compared methotrexate alone versus the addition of nanoparticle technology to assess any signs of drug resistance. In the in vitro study, they implanted osteosarcoma cancer cells into animals and tested tumor growth, body weight, pharmacodynamics, and histology. Overall, MTX-CuB-NLCs demonstrated favorable stability, targeting, and anti-osteosarcoma effects. By stymying the most deleterious dose-limiting effects of conventional anthracyclines, pegylated liposomal delivery systems show great promise in osteosarcoma therapy. Early Phase 1 clinical data (Wen et al. 2022) suggest that pegylated liposomal delivery of doxorubicin preserves antitumor activity with a manageable toxicity profile and no observable short-term decline in cardiac function.
CONCLUSIONS:
Lipid nanocarrier studies suggest greater efficacy and anti-osteosarcoma effects of encapsulated drugs, such as methotrexate. Preclinical nanoparticle delivery of cisplatin and doxorubicin consistently demonstrates enhanced tumor localization, improved bioavailability, and a viable therapeutic model by optimizing drug distribution. By reducing dose-limiting toxicities of conventional treatments, nanoparticles offer a promising framework for improving therapeutic efficacy and patients' quality of life. Continued translational research and larger clinical trials are needed to define their roles in standard treatment protocols.
Embargo Period
5-15-2026
Integration of Nanoparticle Technology in Osteosarcoma Treatment: From Bench to Bedside
Suwanee, GA
INTRODUCTION: Osteosarcoma is a malignant tumor, arising from mesenchymal stem cells located in the metaphyseal region of the long bones. These tumors commonly manifest in a bimodal distribution of children, adolescents, and young adults, with a secondary incidence in the elderly. Osteosarcoma is characterized by complex genomic instability rather than a single driver mutation, with commonly altered genes including TP53, RB1, ATRX, and MDM2. The tumors prefer to be in an acidic, low-oxygen environment that promotes matrix metalloproteinase (MMP) secretion, leading to bone destruction through RANKL pathway activation, pathological angiogenesis, and pulmonary metastasis. Despite the establishment of first-line chemotherapeutic treatment regimens (MAP protocol: cisplatin, doxorubicin, and high-dose methotrexate), traditional treatments expose patients to significant systemic toxicities and chemotherapeutic resistance. Nanoparticle technology offers a highly adaptable platform for targeted drug delivery that addresses these limitations. Structurally, nanoparticles are composed of a core that encapsulates or binds a therapeutic payload and a surface layer that can be chemically engineered to regulate pharmacokinetics, immune recognition, and tissue-specific targeting. Overall, the integration of nanoparticle carriers into osteosarcoma therapy represents an advancement in overcoming therapeutic resistance, minimizing systemic toxicity, and improving patient quality of life.
METHODS: This literature review of nanoparticle technology was conducted utilizing PubMed, NIH, and EBSCO databases, with first-line treatment approaches guided by the National Comprehensive Cancer Network (NCCN). Selected studies incorporated nanoparticle formulations combined with first-line agents. Discussion is organized by preclinical (in vitro and in vivo) and clinical trial evidence.
RESULTS: Among the various nanoparticle modalities, nanostructured lipid carriers (NLCs) represent a particularly promising approach due to biocompatibility, high drug-loading capacity, and sustained-release properties. Hao Li et al. (2025) conducted in vitro and in vivo studies to determine whether combining methotrexate and cucurbitacin with a nanoparticle lipid (MTX-CuB-NLC) carrier can prevent drug resistance, a major barrier to treatment initiation. In the vitro study, they used both solid and liquid lipids to formulate the delivery system, thereby improving drug delivery. They compared methotrexate alone versus the addition of nanoparticle technology to assess any signs of drug resistance. In the in vitro study, they implanted osteosarcoma cancer cells into animals and tested tumor growth, body weight, pharmacodynamics, and histology. Overall, MTX-CuB-NLCs demonstrated favorable stability, targeting, and anti-osteosarcoma effects. By stymying the most deleterious dose-limiting effects of conventional anthracyclines, pegylated liposomal delivery systems show great promise in osteosarcoma therapy. Early Phase 1 clinical data (Wen et al. 2022) suggest that pegylated liposomal delivery of doxorubicin preserves antitumor activity with a manageable toxicity profile and no observable short-term decline in cardiac function.
CONCLUSIONS:
Lipid nanocarrier studies suggest greater efficacy and anti-osteosarcoma effects of encapsulated drugs, such as methotrexate. Preclinical nanoparticle delivery of cisplatin and doxorubicin consistently demonstrates enhanced tumor localization, improved bioavailability, and a viable therapeutic model by optimizing drug distribution. By reducing dose-limiting toxicities of conventional treatments, nanoparticles offer a promising framework for improving therapeutic efficacy and patients' quality of life. Continued translational research and larger clinical trials are needed to define their roles in standard treatment protocols.